案例27基因泰克060315

主题:生物技术,罗氏公司,基因泰克 页:5(1095字) 发布时间:2015年6月6日
BUSB 481 - Professor Coulson
案例27 - 基因泰克公司:收购由罗氏公司后
特里芬达
2015年6月3日
1.执行VRIO分析。什么是Genentech公司的竞争优势,如果有的话?导致Genentech公司的竞争优势显著的资源是文化。这种文化被它的创始合作伙伴罗伯特·斯旺森和赫伯特·博耶灌输。在这种文化R&d集中在应用前沿的科学知识发现和开发最好的一流的药品。文化“个人的创造性和主动性,”帮助建立的声誉,吸引了一些谁被鼓励,不仅对工作与公司目标相关的项目在世界上最好的科学家,也给工作对激起了自己的项目利益。总的文化导致了业内人士的标有高生产力的环境“休闲强度。”

2.将一个PESTEL分析。将在医疗保健和生物仿制药法规变化对基因泰克公司有什么影响?为什么?杵(pestal)分析表明,政治,法律,经济和社会文化环境进行了显著在生物技术领域由2000年年底的改变。经济刺激计划和医疗保健改革法案均带来增强的政府监管的行业,这可能意味着一次新产品的上市可以增加以及潜在的一些产品将不能获得认可,从调整主体意味着销售betway必威官网下载收入可能受到影响。医疗改革法案的具体方面也提出了基因泰克公司的商业模式严重威胁。在生物制品的价格竞争和创新法案允许对生物仿制药,这将有因为产品的开发,并在行业测试相关的显著成本上基因泰克一个显著的影响,缩短审批途径的通道。3.用五力分析。你会如何形容Genentech公司的竞争地位? Threat of Entry: The threat of entry is relatively low as it takes a substantial investment in R&D, facilities and equipment to move into the biotechnology market. Most competitors have backing from large pharmaceutical companies to gain entry. Ranking: Low. Power of Suppliers: Most biotechnology firms produce their own protein structures and have in-house production capabilities. This results in a low rating for power of suppliers. While continued demand growth for these drugs is expected, Genentech should have sufficient production capacity and financial backing through Roche to meet increased production concerns. Ranking: Low. Power of Buyers: Buyer power has traditionally been low in the biotech industry, however as government healthcare reforms have been implemented, HMO's and PPO's have been able to exert more influence over buying power through by mandating patients to use biogeneric drugs. Even with this shifting trend buyer power is still seen to be low - medium. Ranking Low - Medium. Threat of Substitutes: There is an increasing threat of substitutes as other established pharmaceutical companies partner with biotech firms to produce similar products. There is also threat of substitution from biogeneric drugs as patents expire. Ranking: Medium. Rivalry: Each of Genentech's primary product offerings have competition and while patent protection prevents drugs with similar structures it does not prevent drugs that have similar effects or treat similar diseases. Ranking: Low - Medium. Overall, I would say that Genentech's profit potential is strong based on a low - medium ranking in the 5 Forces analysis. 4. Perform a SWOT analysis.

优势:
- 先进的技术能力与生物技术领域的顶尖员工的科学家。- 重大专利和技术突破和商业成功派驻人员。- 行业领先的研究声誉和产品组合。- 非常注重个人的主动性和科研...
继续阅读

请加入StudyModebetway中文官网阅读完整的文档

你可能还会发现这些文件有用

  • 基因泰克案例研究论文
  • 案例研究论文
  • 案例研究论文
  • 案例研究论文
  • 案例研究论文
  • 案例研究论文
  • 梯瓦制药案例研究论文
  • 案例分析PTI研究论文

成为学习模式的一员betway中文官网

注册-它是免费的